1887
  1. Home
  2. Eurosurveillance
  3. Volume 21, Issue 13, 31/Mar/2016
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Influenza A(H1N1)pdm09 viruses predominated in the European influenza 2015/16 season. Most analysed viruses clustered in a new genetic subclade 6B.1, antigenically similar to the northern hemisphere vaccine component A/California/7/2009. The predominant influenza B lineage was Victoria compared with Yamagata in the previous season. It remains to be evaluated at the end of the season if these changes affected the effectiveness of the vaccine for the 2015/16 season.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2016.21.13.30184
2016-03-31
2024-10-14
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2016.21.13.30184
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/21/13/eurosurv-21-30184-3.html?itemId=/content/10.2807/1560-7917.ES.2016.21.13.30184&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Risk Assessment - Seasonal Influenza A(H1N1)pdm09 2016. Geneva: WHO. [Accessed 22 Feb 2016]. Available from: http://www.who.int/influenza/publications/riskassessment_AH1N1pdm09_201602/en/
  2. The Public Health Agency of Sweden. Ovanligt många allvarligt sjuka i influensa 2016. Swedish. [Accessed 22 Feb 2016]. Available from: http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2016/februari/ovanligt-manga-allvarligt-sjuka-i-influensa/
  3. European Centre for Disease Prevention and Control (ECDC). Risk assessment Seasonal influenza 2015-2016 in the EU/EEA countries 2016. Stockholm: ECDC. [Accessed 26 Feb 2016]. Available from: http://ecdc.europa.eu/en/publications/Publications/seasonal-influenza-risk-assessment-2015-2016.pdf
  4. Centers for Disease Control and Prevention (CDC). CDC health advisory. Flu Season Begins: Severe Influenza Illness Reported CDC urges rapid antiviral treatment of very ill and high risk suspect influenza patients without waiting for testing 2016. Atlanta: CDC. [Accessed 22 Feb 2016]. Available from: http://emergency.cdc.gov/han/han00387.asp
  5. World Health Organization Regional Office for Europe (WHO/Europe). Risk assessment of the 2015-2016 influenza season in the WHO European Region, week 40/2015 to week 04/2016 2016. Copenhagen: WHO/Europe. [Accessed 8 Mar 2016]. Available from: http://www.euro.who.int/__data/assets/pdf_file/0011/301115/Risk-assessment-influenza-season-week40-15-to-week04-16.pdf
  6. Broberg E, Snacken R, Adlhoch C, Beauté J, Galinska M, Pereyaslov D, et al. WHO European Region and the European Influenza Surveillance Network. Start of the 2014/15 influenza season in Europe: drifted influenza A(H3N2) viruses circulate as dominant subtype. Euro Surveill. 2015;20(4):21023.  https://doi.org/10.2807/1560-7917.ES2015.20.4.21023  PMID: 25655052 
  7. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation, Summary Europe, September 2015. Stockholm: ECDC; 2015. [Accessed 7 Mar 2016]. Available from: http://ecdc.europa.eu/en/publications/Publications/influenza-virus-characterisation-september-2015.pdf
  8. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation, summary Europe, December 2015. Stockholm: ECDC; 2016. [Accessed 22 Feb 2016]. Available from: http://ecdc.europa.eu/en/publications/Publications/Influenza-Virus-Characterisation-December-2015.pdf
  9. Parida M, Dash PK, Kumar JS, Joshi G, Tandel K, Sharma S, et al. Emergence of influenza A (H1N1)pdm09 genogroup 6B and drug resistant virus, India, January to May 2015. Euro Surveill. 2016;21(4):30124.  https://doi.org/10.2807/1560-7917.ES.2016.21.5.30124  PMID: 26876980 
  10. World Health Organization (WHO). Global epidemiological surveillance standards for influenza 2013. Geneva: WHO. [Accessed 22 Feb 2016]. Available from: http://www.who.int/influenza/resources/documents/WHO_Epidemiological_Influenza_Surveillance_Standards_2014.pdf
  11. European Centre for Disease Prevention and Control (ECDC). Influenza surveillance in Europe 2010-2011. Stockholm: ECDC; 2011. [Accessed 22 Feb 2016]. Available from: http://ecdc.europa.eu/en/publications/Publications/111209_SUR_Influenza_surveillance_Europe%20_2010_2012.pdf
  12. Snacken R, Broberg E, Beauté J, Lozano JE, Zucs P, Amato-Gauci AJ. Influenza season 2012-2013 in Europe: moderate intensity, mixed (sub)types. Epidemiol Infect. 2014;142(9):1809-12.  https://doi.org/10.1017/S0950268814001228  PMID: 24814635 
  13. European Centre for Disease Prevention and Control (ECDC). Influenza in Europe – Season 2013-2014. Stockholm: ECDC; 2014. [Accessed 22 Feb 2016]. Available from: http://ecdc.europa.eu/en/publications/Publications/Influenza-2013-14-season-report.pdf
  14. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation, December 2013. Stockholm: ECDC; 2014. [Accessed 22 Feb 2016]. Available from: http://ecdc.europa.eu/en/publications/Publications/influenza-virus-characterisation-dec-2013.pdf
  15. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2016-2017 northern hemisphere influenza season 2016. Geneva: WHO. [Accessed 25 Feb 2016]. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/201602_recommendation.pdf
  16. Kissling E, Valenciano M. Early influenza vaccine effectiveness results 2015-16: I-MOVE multicentre case-control study. Euro Surveill. 2016;21(6):30134.  https://doi.org/10.2807/1560-7917.ES.2016.21.6.30134  PMID: 26898240 
  17. Koel BF, Mögling R, Chutinimitkul S, Fraaij PL, Burke DF, van der Vliet S, et al. Identification of amino acid substitutions supporting antigenic change of influenza A(H1N1)pdm09 viruses. J Virol. 2015;89(7):3763-75.  https://doi.org/10.1128/JVI.02962-14  PMID: 25609810 
  18. Tate MD, Job ER, Deng YM, Gunalan V, Maurer-Stroh S, Reading PC. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses. 2014;6(3):1294-316.  https://doi.org/10.3390/v6031294  PMID: 24638204 
  19. Wei CJ, Boyington JC, Dai K, Houser KV, Pearce MB, Kong WP, et al. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med. 2010;2(24):24ra21.  https://doi.org/10.1126/scitranslmed.3000799  PMID: 20375007 
  20. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season. Wkly Epidemiol Rec. 2016;91(10):121-32.http://reliefweb.int/sites/reliefweb.int/files/resources/wer9110.pdf PMID: 26971356 
  21. Valenciano M, Kissling E, Reuss A, Jiménez-Jorge S, Horváth JK, Donnell JM, et al. I-MOVE Multicentre Case Control Study Team. The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2). Vaccine. 2015;33(24):2813-22.  https://doi.org/10.1016/j.vaccine.2015.04.012  PMID: 25936723 
  22. Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horváth JK, et al. Joan O´DonellI-MOVE multicentre case–control team. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill. 2016;21(7):30139.  https://doi.org/10.2807/1560-7917.ES.2016.21.7.30139  PMID: 26924024 
  23. Bissielo A, Pierse N, Huang QS, Thompson MG, Kelly H, Mishin VP, et al. SHIVERS. Effectiveness of seasonal influenza vaccine in preventing influenza primary care visits and hospitalisation in Auckland, New Zealand in 2015: interim estimates. Euro Surveill. 2015;21(1):30101.  https://doi.org/10.2807/1560-7917.ES.2016.21.1.30101  PMID: 26767540 
Predominance of influenza A(H1N1)pdm09 virus genetic subclade 6B.1 and influenza B/Victoria lineage viruses at the start of the 2015/16 influenza season in Europe
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Eeva+Broberg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Broberg Eeva</a>, <a href="/search?value1=Angeliki+Melidou&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Melidou Angeliki</a>, <a href="/search?value1=Katarina+Prosenc&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Prosenc Katarina</a>, <a href="/search?value1=Karoline+Bragstad&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bragstad Karoline</a>, <a href="/search?value1=Olav+Hungnes&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hungnes Olav</a>, <a href="/search?value1=on+behalf+of+the+WHO+European+Region+and+the+European+Influenza+Surveillance+Network+members+of+the+reporting+countries&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of the WHO European Region and the European Influenza Surveillance Network members of the reporting countries</a></span>. Predominance of influenza A(H1N1)pdm09 virus genetic subclade 6B.1 and influenza B/Victoria lineage viruses at the start of the 2015/16 influenza season in Europe. <a href="/content/ecdc">Euro Surveill.</a> 2016;21(13):pii=30184. <a href="https://doi.org/10.2807/1560-7917.ES.2016.21.13.30184" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2016.21.13.30184</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 09 Mar 2016;&nbsp;&nbsp; <span class="generated">Accepted</span>: 31 Mar 2016 </span> </p>
/content/10.2807/1560-7917.ES.2016.21.13.30184
/content/10.2807/1560-7917.ES.2016.21.13.30184
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error